Clinical trials: Decompensated Cirrhosis
Decompensated Cirrhosis
A Trial to Study the Influence of Growth Factors on Bone Marrow and Hepatic Regeneration in Patients With Decompensated Cirrhosis.
This will be a randomized double blind study which will be conducted on patients admitted to Department of Hepatology from June 2013 to may 2014 at ILBS, New Delhi.
- Trial name
- NCT01902511
- Testing
- G-CSF+Erythropoetin, G-CSF
- Where
- India
- Volunteers
- 60 people
- Sponsor
- Institute of Liver and Biliary Sciences, India
Cirrhosis
To Study and Compare the Clinical Course and Development of Organ Failure in Severe Acute Hepatitis Without Ascites, Non-cirrhotic and Cirrhotic Patients With Ascites [Acute on Chronic Liver Failure] and Acute Deterioration of Previously Decompensated Cirrhosis.
The study will be conducted on patients admitted to Department of Hepatology from MARCH 2015 to DECEMBER 2016 at ILBS, New Delhi.All patients presenting to ILBS fulfilling the inclusion criteria will be included in the study and…
- Trial name
- NCT02465619
- Where
- India
- Sponsor
- Institute of Liver and Biliary Sciences, India
Cirrhosis
Rifaximin Reduces the Complications of Decompensated Cirrhosis: a Randomized Controlled Trial
Cirrhotic patients are predisposed to intestinal dysmotility, bacterial overgrowth, and increased intestinal permeability all leading to an increase in bacterial translocation and increased endotoxemia.
- Trial name
- NCT02190357
- Testing
- Rifaximin
- Where
- China
- Volunteers
- 200 people
- Sponsor
- Shanghai Changzheng Hospital
Cirrhosis, Ascites
Acute Hemodynamics of Albumin Versus Normal Saline in Cirrhosis
Cirrhosis is frequently complicated by derangement of body fluid homeostasis resulting in accumulation of large amounts of extracellular fluid in the peritoneal cavity (ascites) and interstitial tissue (edema).
- Trial name
- NCT00511394
- Testing
- 20% Human Albumin, Normal Saline
- Where
- India
- Volunteers
- 16 people
- Sponsor
- Govind Ballabh Pant Hospital
Cirrhosis, Liver, AKI
Dextran, a Plasma Expander, Offers New Hope for Patients With Decompensated Liver Cirrhosis and Acute Kidney Injury
A pilot study of Dextran-40 infusion in patients with decompensated cirrhosis presenting with AKI
- Trial name
- NCT03070353
- Testing
- Dextran 40
- Volunteers
- 10 people
- Sponsor
- Ramathibodi Hospital
Decompensated Liver Cirrhosis
Mesenchymal Stem Cells Treatment for Decompensated Liver Cirrhosis
Decompensated liver cirrhosis is a life-threatening chronic liver disease with high mortality. Liver transplantation is the only option that can improve the survival of these patients; however, this procedure is associated with…
- Trial name
- NCT03945487
- Testing
- umbilical cord-derived mesenchymal stem cell, Comprehensive treatment
- Where
- China
- Volunteers
- 200 people
- Sponsor
- Beijing 302 Hospital
Cirrhosis, Acute Liver Failure
Evaluation of Cardiac Function in Acutely Decompensated Cirrhosis
This project aims to investigate cardiac function in patients with cirrhosis in the acute setting. Acute decompensation and acute-on-chronic liver failure are major events in the life of a patient as they herald disease…
- Conditions
- Cirrhosis, Acute Liver Failure, Cardiomyopathies
- Trial name
- DYNACORD-AD (NCT05413083)
- Where
- Romania
- Volunteers
- 70 people
- Sponsor
- Clinical Hospital Colentina
Cirrhosis of the Liver, Ascites
Evaluation of Serum-Derived Bovine Immunoglobulin Protein Isolate in Subjects With Decompensated Cirrhosis With Ascites
This protocol represents an open-label pilot study to assess whether oral administration of SBI in subjects with decompensated cirrhosis with ascites can lead improvements in the management of the disease.
- Conditions
- Cirrhosis of the Liver, Ascites, Spontaneous Bacterial Peritonitis
- Trial name
- NCT02608658
- Testing
- Medical food, EnteraGam (Serum-Derived Bovine Immunoglobulin)
- Where
- United States
- Volunteers
- 11 people, healthy volunteers welcome
- Sponsor
- St. Louis University
Hepatic Impairment, Cirrhosis
Effect of Hepatic Impairment on the Pharmacokinetics and Safety of VIR-2218 and VIR-3434
In this study, a single dose of VIR-2218 up to 200 mg SC or VIR-3434 at 300 mg SC monotherapy or a combination of VIR-2218 and VIR-3434 will be administered to assess the pharmacokinetic (PK) exposure, safety, and tolerability of…
- Trial name
- NCT05484206
- Testing
- VIR-2218, VIR-3434
- Where
- 4 sites in United States
- Volunteers
- 88 people, healthy volunteers welcome
- Sponsor
- Vir Biotechnology, Inc.
Decompensated Liver Cirrhosis, Primary Biliary Cholangitis
LEOPARD Prospective Validation Cohort 1
Intro: The present clinical research protocol is part of the LEOPARD European project (Grant n° 101080964 Horizon Europe) which aims to design and validate new predictive models of mortality among liver transplantation (LT)…
- Conditions
- Decompensated Liver Cirrhosis, Primary Biliary Cholangitis, Primary Sclerosing Cholangitis, Hepato-cellular Carcinoma
- Trial name
- LEOPARD PVC1 (NCT06723275)
- Testing
- Standardized assessments, guided tumor biopsy and biobanking, Standardized assessments and biobanking
- Where
- 8 sites in Belgium, France and 3 more
- Volunteers
- 630 people
- Sponsor
- Assistance Publique - Hôpitaux de Paris
Decompensated Cirrhosis, Liver Transplantation
New Prognostic Predictive Models of Mortality of Decompensated Cirrhotic Patients Waiting for Liver Transplantation
The MELD score is a predictive model of cirrhosis mortality used in France since 2007 to prioritize access to liver transplantation for patients enrolled in the national waiting list.
- Trial name
- SUPERMELD (NCT03820271)
- Testing
- SuperMELD
- Where
- France
- Volunteers
- 501 people
- Sponsor
- Assistance Publique - Hôpitaux de Paris
Cirrhosis, Liver, Rectal Colonization
Longitudinal Surveillance of Rectal Colonization and Transmission by Resistant Bacteria in Acutely Decompensated Cirrhosis
Antimicrobial resistance has emerged as a global threat, and multidrug resistance organisms (MDROs) form one of the foremost challenges in the setting of decompensated cirrhosis.
- Conditions
- Cirrhosis, Liver, Rectal Colonization, Multidrug Resistance Organisms
- Trial name
- NCT06511492
- Testing
- No intervention in this study
- Volunteers
- 1,289 people
- Sponsor
- Nanfang Hospital, Southern Medical University
Liver Cirrhosis
Safety and Efficacy of SHED for Decompensated Liver Cirrhosis
This study is an prospective, randomized control study. Patients with decompensated cirrhosis will be randomly assigned to receive 4 times of SHED treatment plus standard medical care(treatment）or standard medical care (control).
- Trial name
- NCT03957655
- Testing
- SHED group
- Where
- China
- Volunteers
- 40 people
- Sponsor
- Changhai Hospital
Cirrhosis, Portal Hypertension
A Study Evaluating the Utility of Ambrisentan in Lowering Portal Pressure in Patients With Liver Cirrhosis
Endothelin is a human hormone which has been associated with increased portal pressure in patients with liver cirrhosis (also called portal hypertension). Ambrisentan blocks the effects of endothelin.
- Conditions
- Cirrhosis, Portal Hypertension, Ascites
- Trial name
- NCT03827200
- Testing
- Ambrisentan
- Where
- 6 sites in Spain
- Volunteers
- 19 people
- Sponsor
- Noorik Biopharmaceuticals AG